Kyle Robertson's Revolution Venture Studios Aims to Build Healthcare Companies From the Idea Up

After helping build two fast-growing telehealth businesses, Kyle Robertson is now focused on a model that could produce many companies instead of one. His New York-based venture studio creates startups from scratch, supplying the idea, the team and the first round of capital.

As reported by the South Florida Business Journal, Robertson is the founder and managing partner of Revolution Venture Studios (RVS), which develops, funds and launches companies in healthcare, wellness and technology. He combines that role with running Zealthy, the digital health company he started in 2023. The studio is his attempt to turn the lessons of building companies at high speed into a process other entrepreneurs can repeat.

Robertson's path into healthcare technology began with Cerebral, the virtual mental health company he co-founded in 2020. It launched just as the COVID-19 pandemic pushed telehealth from a niche option into a primary way for millions of Americans to see a clinician. Cerebral expanded quickly under his leadership, eventually serving close to a million patients and reaching a valuation of $4.8 billion, before Robertson left in 2022. His next venture, Zealthy, took a wider view of digital care. The platform covers both physical and mental health and is meant to make some types of treatment available without a trip to a traditional clinic, with the long-term goal of becoming a large and trusted provider of virtual healthcare. While building it, Robertson grew more interested in how the experience he had gained could help other founders, and that interest led to RVS.

The studio works in a different order from a typical venture capital firm. In the usual sequence, entrepreneurs form a company, build a product and assemble a team before asking investors for money. RVS starts earlier. It generates business concepts, tests whether they are worth pursuing and only then recruits co-founders to turn them into operating companies, providing funding at the very beginning. Robertson stays closely involved as a mentor and, in some cases, as a co-founder and board chair, reflecting his belief that early-stage founders need practical support alongside capital. The studio says it looks for ambitious people prepared to move fast, take calculated risks and work with the intensity that building from nothing requires. Its co-founders include experienced entrepreneurs as well as executives brought in to serve as CEOs and CTOs, and the leadership team offers structured guidance while each founder stays responsible for building the business. Because the studio runs several companies at once, lessons learned in one can be applied to the next, whether they concern hiring, product development, healthcare regulation, clinical operations or checking that customers will actually pay for a solution.

Much of the studio's current work targets a well-known problem in medicine: administrative overload. Clinicians spend a large share of their time documenting visits, working through administrative systems and completing paperwork, which leaves less time for patients. Robertson sees this as an area where AI can make a real difference, and RVS is incubating companies that build software to lighten that load. The portfolio covers several directions:

• CareBeam, an AI-powered documentation platform that converts conversations between clinicians and patients into structured clinical notes;

• Bioverse, which delivers longevity-focused care online;

• Amara, a company operating in the medical spa market;

• other ventures working on healthcare software and AI applications, some of which are still in stealth while they develop products for healthcare providers.

For Robertson, healthcare offers so many opportunities because many of its processes remain costly, fragmented or confusing for patients. Cerebral showed how large virtual mental health services could become, and Zealthy is a broader effort to deliver care directly to consumers online. With RVS, he is trying to address many parts of the system at the same time, building companies and developing the people who will lead them. If the approach works, the studio could repeatedly turn specific healthcare problems into technology businesses, giving each founding team capital, operating experience and mentorship from the first day. Whether those companies go on to lead their markets is still an open question, but Robertson's bet is that the next wave of AI-driven change in healthcare will come from a group of ambitious founders working on the system's gaps in parallel.